Artes Medical, Inc. Files Registration Statement with the SEC for Proposed Initial Public Offering.

SAN DIEGO -- Artes Medical, Inc. announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock. The number of shares to be offered and the price range of the proposed offering have not yet been determined. All of the shares of common stock will be offered by the Company. E[acute accent]Cowen and Company, LLC and Lazard Capital Markets LLC will act as joint book-running managers of the proposed offering. Stifel, Nicolaus & Company, Incorporated will act as co-manager of the proposed offering. The proposed offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to this proposed offering may be obtained from the Securities and Exchange Commission website at www.sec.gov or by contacting either Cowen and Company, LLC or Lazard Capital Markets LLC c/o ADP Financial Services, 1155 Long Island Ave., Edgewood, NY 11717 or by fax [phone]. E[acute accent]A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior to the time that the registration statement becomes effective. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The prospectus related to the proposed offering will be included in the registration statement.

E[acute accent]About Artes Medical

E[acute accent]Artes Medical, Inc. is a fully integrated medical technology company focused on developing, manufacturing and commercializing a new category of permanent aesthetic micro-injectable products for the dermatology and plastic surgery markets. The Company's initial product candidate, ArteFill, is currently under review by the U.S. Food and Drug Administration for the correction of facial wrinkles known as smile lines, or nasolabial folds. Artes Medical, Inc. was founded in 1999, and is based in San Diego, California.

E[acute accent]Cautionary Statement

E[acute accent]This news release contains forward-looking statements that are based on the Company's current beliefs and assumptions and on information currently available to its management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. As a result of these risks, uncertainties and other factors, readers are cautioned not to place undue reliance on any forward-looking statements included in this press release. These forward-looking statements represent beliefs and assumptions only as of the date of this news release, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.